Alcohol Use Disorder Clinical Trial
Official title:
Impact of Oxytocin on Neurobiologic Substrates of Social Stress in Individuals With Alcohol Use Disorder
Individuals with alcohol use disorder (AUD) will complete one functional Magnetic Resonance Imaging (fMRI) scanning visit. Prior to the scan, individuals will receive a nasal spray of either 24 international units (IU) of oxytocin (OT), or placebo (PBO). During the scan, they will perform the Montreal Imaging Stress Task (MIST), a social stress task. Subjective craving and anxiety data will be collected.
Participants: Twenty-four individuals with AUD will be recruited through the Clinical Intake
and Assessment (CIA) Core of the Alcohol Research Center (ARC). Screening and basic
assessments will be conducted by the CIA Core to determine eligibility and suitability for
participation in this pilot project. Each individual will sign an Institutional Review Board
(IRB)-approved informed consent form.
Study Visit Assessments: The Drinking Motives Questionnaire Revised will be used to assess
motivation for drinking across four subscales: (1) coping motives; (2) social motives; (3)
conformity motives; and (4) enhancement motives. The Form 90 will be used to assess daily
alcohol consumption in the 90 days prior to the study visit and the time from last drink . A
modification of the Within Session Rating Scale will be used to assess craving and mood.
Study Visit Procedures: Participants will be asked to arrive at the Addiction Sciences
Division on the study visit day. Female participants will have their urine tested for
pregnancy. Females who test positive for pregnancy will be excluded. All participants will be
tested for drugs of abuse and alcohol. Patients testing positive for drugs, with the
exception of marijuana, will be excluded; patients testing positive for alcohol may be
re-scheduled. Participants will be asked about substance use in the last 90 days and will
fill out the Drinking Motives Questionnaire. Subjects who have not had a research physical
exam within the last 30 days will have a physical completed. They will then be escorted to
the scanner at 30 Bee Street.
The study will use a double-blind placebo controlled design. Intranasal OT (n=12) or PBO
(n=12) sprays will be administered at 11:30 am, approximately 45 min prior to the scanning
session. This dose and timing of OT administration were selected based on the literature.
MIST Procedure: The study will use a block design of three, 6-min runs separated by 2-min of
rest for feedback, for a total of 24 min. During each run, participants will be exposed to
40-sec blocks of three different conditions (rest, control, and experimental). Prior to the
task, participants will are shown images of what the screen will look like during each
condition. The participants will be instructed to relax during the rest condition and focus
on the screen. During the control condition, the participants will be asked to answer math
problems as accurately as possible but will also be told that their responses will not be
recorded. During the experimental condition, the participants will be asked to perform the
math task as quickly and accurately as possible. A performance bar located on the screen will
allow them to see their performance as compared to an "average" person. The participants will
be told that the average person would answer about 85% of the problems correctly; however,
the program limits the participants' performance rate to between 35-45%. A time limit will be
enforced throughout the experimental condition. After each run, the participants will be
given negative feedback from the investigator.
Blood Oxygen Level Dependent (BOLD)-fMRI Procedure: Data will be acquired on a Siemens Trio
3T scanner in MUSC's Center for Biomedical Imaging. For co-registration and normalization of
functional images, a high resolution T1-weighted Magnetization-Prepared Rapid Acquisition
with Gradient Echo (MPRAGE) anatomical image will be acquired with the following parameters:
Time of Repetition (TR)= 2100 ms, Echo Time (TE)= 4.18 ms, flip angle= 12°, field of view=
256 mm, slice thickness= 1.0 mm. The scanning planes will be oriented parallel to the
anterior commissure-posterior commissure line. Participants will be asked to relax and keep
their eyes opened and fixed on a cross-hair for 6 min while resting state data are collected.
Participants will then complete the MIST. T2*-weighted gradient-echo planar images (EPI) will
be acquired with the following parameters: TR= 2000 ms, TE= 27 ms, flip angle= 76º, matrix 64
x 64, field of view= 23 cm, slice thickness= 3.7 mm with no gap, with 36 slices to cover the
entire brain.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04788004 -
Long-term Recovery: Longitudinal Study of Neuro-behavioral Markers of Recovery and Precipitants of Relapse
|
||
Recruiting |
NCT05684094 -
Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep to Reward- and Stress-Related Brain Function
|
N/A | |
Completed |
NCT03406039 -
Testing the Efficacy of an Online Integrated Treatment for Comorbid Alcohol Misuse and Emotional Problems
|
N/A | |
Completed |
NCT03573167 -
Mobile Phone-Based Motivational Interviewing in Kenya
|
N/A | |
Completed |
NCT04817410 -
ED Initiated Oral Naltrexone for AUD
|
Phase 1 | |
Active, not recruiting |
NCT04267692 -
Harm Reduction Talking Circles for American Indians and Alaska Natives With Alcohol Use Disorders
|
N/A | |
Completed |
NCT03872128 -
The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders
|
Phase 1 | |
Completed |
NCT02989662 -
INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers
|
Phase 1/Phase 2 | |
Recruiting |
NCT06030154 -
Amplification of Positivity for Alcohol Use
|
N/A | |
Active, not recruiting |
NCT05419128 -
Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19
|
N/A | |
Completed |
NCT04564807 -
Testing an Online Insomnia Intervention
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT04203966 -
Mental Health and Well-being of People Who Seek Help From Their Member of Parliament
|
||
Recruiting |
NCT05861843 -
Craving Assessment in Patients With Alcohol Use Disorder Using Virtual Reality Exposure
|
||
Terminated |
NCT04404712 -
FAAH Availability in Psychiatric Disorders: A PET Study
|
Early Phase 1 | |
Enrolling by invitation |
NCT04128761 -
Decreasing the Temporal Window in Individuals With Alcohol Use Disorder
|
N/A | |
Not yet recruiting |
NCT06444243 -
Psilocybin-assisted Therapy for Alcohol Use Disorder
|
Phase 2 | |
Not yet recruiting |
NCT06163651 -
Evaluating a One-Year Version of the Parent-Child Assistance Program
|
N/A | |
Not yet recruiting |
NCT06337721 -
Preventing Alcohol Use Disorders and Alcohol-Related Harms in Pacific Islander Young Adults
|
N/A | |
Enrolling by invitation |
NCT02544581 -
Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare
|
N/A |